Effects of long-term administration of interferon a in two models of liver fibrosis in rats

Journal of Hepatology

Volumn 29, Issue 2, 1998, Pages 263-270

  Fort, Joël ^a   Pilette, Christophe ^a   Veal, Nary ^a   Oberti, Frédéric ^a   Gallois, Yves ^b   Douay, Olivier ^b   Rosenbaum, Jean ^c   Calès, Paul ^a,d  

^a Lab d'Hemodynamique Splanchnique   (France)

^b Angers   (France)

^c Grp Rech Pour l'Etud Foie U   (France)

^d ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

Bile duct ligation; CCl4; Hepatic fibrosis; Interferon a; Portal hypertension; Rats

Indexed keywords

ALPHA2A INTERFERON; CARBON TETRACHLORIDE; FIBRONECTIN; HYALURONIC ACID; HYDROXYPROLINE; MESSENGER RNA; PLACEBO; PROCOLLAGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT LIGATION; CONTROLLED STUDY; LIVER FIBROSIS; LONG TERM CARE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032146969     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(98)80012-3     Document Type: Article

References (47)

1. Friedman SL. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N Engl J Med. 328:1993;1828-1835.
2. Pinzani M. Hepatic stellate (Ito) cells: expanding roles for a liver-specific pericyte. J Hepatol. 22:1995;700-706.
3. Berman B, Duncan M. Short-term cheloid treatment in vivo with human interferon alpha-2b results in a selective and persistent normalization of keloidal fibroblast collagen, glycosaminoglycan, and collagenase production in vitro. J Am Acad Dermatol. 21:1989;694-702.
4. Duncan M, Berman B. Persistence of a reduced-collagen-producing phenotype in cultured scleroderma fibroblasts after short term exposure to interferons. J Clin Invest. 79:1987;1318-1324.
5. Goldring M, Sandell L, Stephenson M, Krone SM. Immune interferon suppresses levels of procollagen mRNA and type II collagen synthesis in cultured human articular and costal chondrocytes. J Biol Chem. 19:1986;9049-9056.
6. Rockey DC, Maher J, Jarnagin W, Gabbion IG, Friedman S. Inhibition of rat hepatic lipocyte activation in culture by interferon γ Hepatology. 16:1992;776-784.
7. Mallat A, Preaux A-M, Blazejewski S, Rosenbaum J, Dhumeaux D, Mavier P. Interferon α and γ inhibit proliferation and collagen synthesis of human Ito cells in culture. Hepatology. 21:1995;1003-1010.
8. Baroni G, D'Ambrosio Letizia, Curto P, Casini A, Mancini R, et al. Interferon gamma decreases hepatic stellate cell activation and extracellular matrix deposition in rat liver fibrosis. Hepatology. 23:1996;1189-1199.
9. Garcia-Tsao G, Rodriguez-Perez F, Blei AT, Groszmann RJ. Treatment with interferon reduces portal pressure in patients with chronic hepatitis C. A randomized placebo-controlled trial [abstract]. Gastroenterology. 110:1996;1193.
10. Feldmann G. Critical analysis of the methods used to morphologically quantify hepatic fibrosis. J Hepatol. 22:1995;49-54. (Suppl 2).
11. Oberti F, Pilette C, Rifflet H, Maiga M, Moreau A, Gallois Y, et al. Effects of simvastatin, pentoxyfylline and spironolactone on hepatic fibrosis and portal hypertension in cirrhotic rats. J Hepatol. 26:1997;1363-1371.
12. Oberti F, Rifflet H, Maiga M, Pilette C, Gallois Y, Douay O, et al. Prevention of portal hypertension by propranolol and spironolactone in rats with bile duct ligation. J Hepatol. 26:1997;167-173.
13. Rockey D. The cellular pathogenesis of portal hypertension: stellate cell contractility, endothelin and nitric oxide. Hepatology. 25:1997;2-5.
14. Lebrec D. Animals models of portal hypertension. Okuda K, Benhamou JP. Portal Hypertension: Clinical and Physiological Aspects. 1991;101-113 Springer-Verlag, Tokyo.
15. Proctor E, Chatamra K. High yield micronodular cirrhosis in the rat. Gastroenterology. 83:1982;1183-1190.
16. Halvorsen JF, Myking AO. The porto-systemic collateral pattern in the rat. Eur Surg Res. 6:1974;183-195.
17. Jamall IS, Finelli VN, Que Hee SS. A simple method to determine nanogram levels of 4-hydroxyproline in biological tissues. Anal Biochem. 112:1981;70-75.
18. Chomczinski P, Sacchi N. Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem. 162:1987;156-159.
19. Puissant C, Houdebine I-M. An improvement of the single-step method of RNA isolation by acid guanidium-phenol-chloroform extraction. Biotechniques. 8:1990;148-149.
20. Scharzbauer JE, Tamkun JW, Lemischka IR, Hynes RO. Three different fibronectin mRNAs arise by alternative splicing within the coding region. Cell. 35:1983;421-431.
21. Genovese C, Rove D, Kream B. Construction of DNA sequences complementary to rat alpha 1 and alpha 2 collagen mRNA and their use in studying the regulation of type I collagen by 1,25-dihydroxyvitamin D. Biochemistry. 23:1984;6210-6216.
22. Selden C, Farnaud S, Ding SF, Habib Nagy, Foster C, Hodgson H. Expression of hepatocyte growth factor mRNA, and c-met mRNA hepatocyte growth factor in human liver tumours. J Hepatol. 21:1994;227-234.
23. Camps J, Castilla A, Ruiz J. Randomized trial of lymphoblastoid α interferon in chronic hepatitis C. Effects on inflammation, fibrogenesis and viremia. J Hepatol. 17:1993;390-396.
24. Castilla A, Prieto J, Fausto N. Transforming growth factors β1 and α in chronic liver disease. Effects of interferon alfa therapy. N Engl J Med. 324:1991;933-940.
25. Guéchot J, Loria A, Serfaty L, Giral P, Giboudeau J, Poupon R. Serum hyaluronan as a marker of liver fibrosis in chronic viral hepatitis C: effect of α-interferon therapy. J Hepatol. 22:1995;22-26.
26. Hiramatsu N, Hayashi N, Kasahara A. Improvement of liver fibrosis in chronic hepatitis C patients with natural interferon α J Hepatol. 22:1995;135-142.
27. Schvarz R, Glaumann H, Weiland O, Norkrans G, Wejstal R, Fryden A. Histological outcome in interferon alpha-2b treated patients with chronic posttransfusion non-A, non-B hepatitis. Liver. 11:1991;30-38.
28. Tran Van Nhieu J, Deugnier Y, Métreau JM, Lemonnier C, Dhumeaux D, Zafrani ES. Histological response to interferon-α (IFN α) therapy in chronic hepatitis C: Improvement of necrosis and fibrosis [abstract]. J Hepatol. 18:1993;S181. (Suppl 1).
29. Kasahara A, Hayashi N, Hiramatzu N, Oshita M, Hagiwara H, Katayama K, et al. Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C. A multicenter randomized controlled trial. Hepatology. 21:1995;291-297.
30. Manabe N, Chevallier M, Chossegros P, Causse X, Guerret S, Trépo C, et al. Interferon alpha-2b therapy reduces liver fibrosis in chronic non-A, non-B hepatitis: a quantitiative histological evaluation. Hepatology. 18:1993;1344-1349.
31. Mathurin P, Thévenot T, Sobewski R, Moussali J, Charlotte F, Opolon P, et al. Six months with interferon alpha (IFN) decrease the progression of liver fibrosis and activity in patients with chronic hepatitis C without normalization of ALT at 3 months (NR-3M) [abstract]. Hepatology. 24:1996;157.
32. Guido M, Rugge M, Chemello L, Leandro G, Fattovich G, Guistina G, et al. Liver stellate cells in chronic viral hepatitis: the effect of interferon therapy. J Hepatol. 24:1996;301-307.
33. Muriel P. Alpha-interferon prevents liver collagen deposition and damage induced by prolonged bile duct ligation in the rat. J Hepatol. 24:1996;614-621.
34. Podevin P, Rosmorduc O, Conti F, Veyrunes C, Poupon R. Les acides biliaires modulent l'activité biologique de l'interféron [abstract]. Gastroenterol Clin Biol. 21:1997;86.
35. Zimmerman H, Blaser H, Zimmerman A, Reichen J. Effect of development on the functional and histological changes induced by bile-duct ligation in the rat. J Hepatol. 20:1994;231-239.
36. Kocic G, Kocic R, Milenovic M, Andrejevic-Koracevic S, Kocic B. Interferon-alpha-induced modification of liver adenosine metabolism: a possible mechanism of antiproliferative activity. J Hepatol. 26:1997;158. (suppl 1).
37. Moreno M, Muriel P. Remission of liver fibrosis by interferon α-2b. Bio Pharmacology. 4:1995;515-520.
38. Duncan MR, Berman B. Differential regulation of glycosaminoglycan, fibronectin, and collagenase production in cultured human dermal fibroblasts by interferon-alpha, beta, and -gamma. Arch Dermatol Res. 281:1989;11-18.
39. 2b increases fibrolysis in fibrotic livers from bile duct ligated rats: possible participation of the plasminogen activator. Pharmacology. 51:1995;341-346.
40. Edwards MJ, Keller BJ, Kauffman FC, Thurman RG. The involvement of Kupffer cells in carbon tetrachloride toxicity. Toxicol Appl Pharmacol. 119:1993;27.
41. Tuchweber B, Desmoulières A, Bochaton-Piallat ML, Rubbia-Brandt L, Gabbiani G. Proliferation and phenotypic modulation of portal fibroblasts in the early stages of cholestatic fibrosis in the rat. Lab Invest. 74:1996;265-267.
42. Abdel-Razzak Z, Loyer P, Fautel A, Gautier JC, Corcos L, Turlin B, et al. Cytokines down-regulate expression of major cytochrome P450 enzymes in adult human hepatocytes in primary culture. Mol Pharmacol. 44:1993;707-715.
43. Sakai H, Okamoto T, Kikkawa Y. Suppression of hepatic drug metabolism by the interferon inducer, polyriboinosinic acid: polyribocitidylic acid. J Pharmacol Exp Ther. 363:1992;381-386.
44. D'Almeida MS, Caimail S, Lebrec D. Validation of transit-time ultrasound flow probes to directly measure portal blood flow in conscious rats. Am J Physiol. 271:1996;H2701-H2709.
45. Oberti F, Veal N, Fort J, Pilette C, Calès P. Measurement of whole porto-systemic blood flow and cardiac output by transit time ultrasound in cirrhotic rats. J Hepatol. 26:1997;235. (Suppl 1).
46. Colombato LA, Albillos A, Genecin P, Sarin S, Groszmann RJ. Prevention of portal systemic shunting in propranolol-treated and in sodium-restricted cirrhotic rats [abstract]. Gastroenterology. 100:1990;73.
47. Gerathy JG, Angerson WJ, Carter DC. Portal venous pressure and portosystemic shunting in experimental portal hypertension. Am J Physiol. 257:1989;G52-G57.